Abstract
Melatonin is a pineal hormone which basically acts through membrane receptors, but also as a free radical scavenger (requiring no receptors), and by binding to intracellular sites (calmodulin and nuclear receptors). Membrane receptors (MT1, MT2) are associated to G-proteins linked to inhibition of adenylyl cyclase and decrease of cAMP, and are expressed by almost all structures of the CNS (especially hypothalamic suprachiasmatic nucleus and pars tuberalis of the pituitary), as well as in peripheral tissues (gastrointestinal tract, thymus, smooth muscle of blood vessels, adipocytes, lymphocytes, etc). Among the actions attributed to melatonin are those of antioxidant, controller of circadian rhythms (especially sleep-wake and core body temperature), immunomodulation, antidepressant, etc. This wide spectrum of actions suggests many possible therapeutic applications for melatonin. However, its use as a drug presents some limitations (to optimise pharmacological responses of each subtype or receptors, its rapid metabolic inactivation, etc.) that have caused many laboratories to develop analogues without the above mentioned problems. Two are the patented melatoninergic drugs with more interesting properties: one is ramelteon (US6034239; Rozerem™), approved by the FDA for the long-term treatment of sleep disturbances characterized by difficulty with sleep onset; the second, agomelatine (US5318994; Valdoxan™), which is completing the phase III trial, was designed for the treatment of symptoms of major depressive disorders, particularly anxiety, sleep troubles and circadian disturbances.
Keywords: Melatonin, agomelatine, valdoxan, ramelteon, rozerem, sleep troubles, depression, MT1 melatonin receptors, MT2 melatonin receptors
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued)
Title: Melatonin and Melatoninergic Drugs as Therapeutic Agents: Ramelteon and Agomelatine, the Two Most Promising Melatonin Receptor Agonists
Volume: 1 Issue: 2
Author(s): Emilio J. Sanchez-Barcelo, Carlos M. Martinez-Campa, Maria D. Mediavilla, Alicia Gonzalez, Carolina Alonso-Gonzalez and Samuel Cos
Affiliation:
Keywords: Melatonin, agomelatine, valdoxan, ramelteon, rozerem, sleep troubles, depression, MT1 melatonin receptors, MT2 melatonin receptors
Abstract: Melatonin is a pineal hormone which basically acts through membrane receptors, but also as a free radical scavenger (requiring no receptors), and by binding to intracellular sites (calmodulin and nuclear receptors). Membrane receptors (MT1, MT2) are associated to G-proteins linked to inhibition of adenylyl cyclase and decrease of cAMP, and are expressed by almost all structures of the CNS (especially hypothalamic suprachiasmatic nucleus and pars tuberalis of the pituitary), as well as in peripheral tissues (gastrointestinal tract, thymus, smooth muscle of blood vessels, adipocytes, lymphocytes, etc). Among the actions attributed to melatonin are those of antioxidant, controller of circadian rhythms (especially sleep-wake and core body temperature), immunomodulation, antidepressant, etc. This wide spectrum of actions suggests many possible therapeutic applications for melatonin. However, its use as a drug presents some limitations (to optimise pharmacological responses of each subtype or receptors, its rapid metabolic inactivation, etc.) that have caused many laboratories to develop analogues without the above mentioned problems. Two are the patented melatoninergic drugs with more interesting properties: one is ramelteon (US6034239; Rozerem™), approved by the FDA for the long-term treatment of sleep disturbances characterized by difficulty with sleep onset; the second, agomelatine (US5318994; Valdoxan™), which is completing the phase III trial, was designed for the treatment of symptoms of major depressive disorders, particularly anxiety, sleep troubles and circadian disturbances.
Export Options
About this article
Cite this article as:
Emilio J. Sanchez-Barcelo , Carlos M. Martinez-Campa , Maria D. Mediavilla , Alicia Gonzalez , Carolina Alonso-Gonzalez and Samuel Cos , Melatonin and Melatoninergic Drugs as Therapeutic Agents: Ramelteon and Agomelatine, the Two Most Promising Melatonin Receptor Agonists, Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) 2007; 1 (2) . https://dx.doi.org/10.2174/187221407780831984
DOI https://dx.doi.org/10.2174/187221407780831984 |
Print ISSN 1872-2148 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3334 |
Related Articles
-
Low Concentration of Caffeine Inhibits the Progression of the Hepatocellular Carcinoma <i>via Akt</i> Signaling Pathway
Anti-Cancer Agents in Medicinal Chemistry <i>Uncaria tomentosa</i> (Willd. ex Schult.): Focus on Nutraceutical Aspects
Current Bioactive Compounds Oncolytic Virotherapy for Breast Cancer Treatment
Current Gene Therapy TNF-Related Apoptosis-Inducing Ligand (TRAIL) as a Pro-Apoptotic Signal Transducer with Cancer Therapeutic Potential
Current Pharmaceutical Design SANTAVAC ™: A Novel Universal Antigen Composition for Developing Cancer Vaccines
Recent Patents on Biotechnology Structure and Ligand Based Drug Design Strategies in the Development of Novel 5- LOX Inhibitors
Current Medicinal Chemistry Mechanosensitive Ion Channels as Drug Targets
Current Drug Targets - CNS & Neurological Disorders Merlin, a “Magic” Linker Between the Extracellular Cues and Intracellular Signaling Pathways that Regulate Cell Motility, Proliferation, and Survival
Current Protein & Peptide Science Mode of Action of Long-Term Low-Dose Macrolide Therapy for Chronic Sinusitis in the Light of Neutrophil Recruitment
Current Drug Targets - Inflammation & Allergy Recent Advances in Optical Cancer Imaging of EGF Receptors
Current Medicinal Chemistry Blind Snipers: Relevant Off Target Effects of Non-chemotherapeutic Agents in Oncology: Review of the Literature
Reviews on Recent Clinical Trials The Exploitation of Toll-like Receptor 3 Signaling in Cancer Therapy
Current Pharmaceutical Design Gene Therapy for Gastric Diseases
Current Gene Therapy Early Post-Operative Neuroimaging After Surgery for Malignant Glioma
Current Medical Imaging A New Frontier in the Treatment of Cancer: NK-1 Receptor Antagonists
Current Medicinal Chemistry Pyruvate Kinase M2: Regulatory Circuits and Potential for Therapeutic Intervention
Current Pharmaceutical Design Opportunities and Challenges for Host-Directed Therapies in Tuberculosis
Current Pharmaceutical Design Emerging Strategies and Challenges for Controlled Delivery of Taxanes: A Comprehensive Review
Current Drug Metabolism New Perspective on the Dual Functions of Indirubins in Cancer Therapy and Neuroprotection
Anti-Cancer Agents in Medicinal Chemistry Endocytosis, Intracellular Traffic and Fate of Cell Penetrating Peptide Based Conjugates and Nanoparticles
Current Pharmaceutical Design